Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom D who wrote (327)	12/5/1997 10:27:00 PM
From: Tom D	Read Replies (2) of 887

A little more on DepoMorph... I would like to append my comments about DepoMorph. I think problems with "DepoMorph overdosage" will be quite rare. Please let me emphasize that the first market for DepoMorph will be for EPIDURAL analgesia. The intravenous concentrations and systemic effects of morphine in patients getting epidural DepoMorph are minimal. Lets review several features of DepoMorph: 1) There is a wider range of acceptable therapeutic concentrations for morphine in the epidural space than in the bloodstream. 2) While pain delays patient healing, systemic use of narcotics delays the recovery of the patient's bowels postoperatively. One key advantage of DepoMorph is expected shortening of the average length of hospitalization compared to PCA (patient-controlled analgesia) which is usually morphine or demerol delivered intravenously and therefore systemically. 3) Another important advantage is the elimination of risk of epidural catheter breakage, infection and incorrect placement. Add to this the elimination of the time and equipment costs of PCA. The more I read and think about DepoMorph, the more I like it. :>) Tom D.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next